Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer

BACKGROUND: Oncolytic immunotherapy represents a unique therapeutic platform for the treatment of cancer. Here, we evaluated the safety and efficacy of the combination of pexastimogene devacirepvec (PexaVec) plus durvalumab (anti-programmed death ligand 1) with and without tremelimumab (anti-cytotox...

Descripción completa

Detalles Bibliográficos
Autores principales: Monge, Cecilia, Xie, Changqing, Myojin, Yuta, Coffman, Kelley, Hrones, Donna Mabry, Wang, Sophie, Hernandez, Jonathan M, Wood, Bradford J, Levy, Elliot B, Juburi, Israa, Hewitt, Stephen M, Kleiner, David E, Steinberg, Seth M, Figg, William D, Redd, Bernadette, Homan, Philip, Cam, Maggie, Ruf, Benjamin, Duffy, Austin G, Greten, Tim F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923269/
https://www.ncbi.nlm.nih.gov/pubmed/36754451
http://dx.doi.org/10.1136/jitc-2022-005640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923269/
https://www.ncbi.nlm.nih.gov/pubmed/36754451
http://dx.doi.org/10.1136/jitc-2022-005640

Ejemplares similares